Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Advanced Breast Cancer × sacituzumab govitecan × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 7 Breast Neoplasms 7 Urinary Bladder Neoplasms 4 Carcinoma, Transitional Cell 3 Small Cell Lung Carcinoma 2 Endometrial Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Locally Advanced Non-resectable Breast Cancer 1 Prostatic Neoplasms, Castration-Resistant 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Meningeal Carcinomatosis 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1 Carcinoma, Small Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Advanced Breast Cancer 1

Interventions

sacituzumab govitecan 1 eribulin 1 balixafortide 1 Taxes 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06612203 2025-12-05

WIN-B

MedSIR

Phase 1/2 Active not recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡